Dr Edmund O'Flaherty, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Dr Edmund O'Flaherty shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.

Solutions for Small Intestinal Bacterial Overgrowth

The Epoch Times
23 June 2021
https://www.theepochtimes.com/solutions-for-small-intestinal-bacterial-overgrowth_3783088.html

Breast and Colon Cancer by Dr Yusuf Saleeby 2021 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Dr Yusuf Saleeby: General Preventive and Integrative Medicine/ Restorative Medicine / Functional Medicine, presents on Breast and Colon Cancer.

Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone

Cancer Lett
29 March 1996
https://pubmed.ncbi.nlm.nih.gov/8620464/

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Cochrane Database Syst Rev
05 June 2018
https://www.ncbi.nlm.nih.gov/pubmed/29869799

Severe pruritus of cholestasis in disseminated cancer: developing a rational treatment strategy. A case report

J Pain Symptom Manage
January 2005
https://www.sciencedirect.com/science/article/pii/S0885392404003914

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders

Int J Pharm Compd
Mar-Apr 2010
https://mail.google.com/mail/u/0?ui=2&ik=b5d7923c33&attid=0.2&permmsgid=msg-f:1668161843235939361&th=1726805badf06421&view=att&disp=safe

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway

Int Immunopharmacol
June 2020
https://pubmed.ncbi.nlm.nih.gov/32171145/?from_single_result=32171145&expanded_search_query=32171145

Low-dose Naltrexone Targets the Opioid Growth Factor-Opioid Growth Factor Receptor Pathway to Inhibit Cell Proliferation: Mechanistic Evidence From a Tissue

Exp Biol Med (Maywood)
September 2011
https://pubmed.ncbi.nlm.nih.gov/21807817/

Akbar Khan, MD - Cancer Case Studies (2016 Conference) (LDN, low dose naltrexone)

In this presentation Dr Khan talks about many case studies involving Transitional cell carcinoma (TCC), colon cancer and Adenoid cystic carcinoma (ACC), explaining how Low Dose Naltrexone (LDN) can improve the lives of cancer patients.